How to Transition from Single‐Gene Pharmacogenetic Testing to Preemptive Panel‐Based Testing: A Tutorial
- 6 July 2020
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 108 (3), 557-565
- https://doi.org/10.1002/cpt.1912
Abstract
There have been significant advancements in precision medicine and approaches to medication selection based on pharmacogenetic results. With the availability of direct‐to‐consumer genetic testing and growing awareness of genetic inter‐individual variability, patient demand for more precise, individually tailored drug regimens is increasing. The University of Florida (UF) Health Precision Medicine Program (PMP) was established in 2011 to improve integration of genomic data into clinical practice. In the ensuing years, the UF Health PMP has successfully implemented several single‐gene tests to optimize the precision of medication prescribing across a variety of clinical settings. Most recently, the UF Health PMP launched a custom‐designed pharmacogenetic panel including pharmacogenes relevant to supportive care medications commonly prescribed to patients undergoing chemotherapy treatment, referred to as “GatorPGx”. This tutorial provides guidance and information to institutions on how to transition from the implementation of single‐gene pharmacogenetic testing to a preemptive panel‐based testing approach. Here, we demonstrate application of the preemptive panel in the setting of an adult solid tumor oncology clinic. Importantly, the information included herein can be applied to other clinical practice settings.Keywords
Funding Information
- University of Florida Health
- College of Medicine, University of Florida
This publication has 43 references indexed in Scilit:
- Preemptive Clinical Pharmacogenetics Implementation: Current Programs in Five US Medical CentersAnnual Review of Pharmacology and Toxicology, 2015
- Useless Until Proven Effective: The Clinical Utility of Preemptive Pharmacogenetic TestingClinical Pharmacology & Therapeutics, 2014
- Pharmacogenomic testing: the case for CYP2C19 proton pump inhibitor gene–drug pairsPharmacogenomics, 2014
- Implementation of pharmacogenetics: The University of Maryland personalized anti‐platelet pharmacogenetics programSeminars in Medical Genetics, Part C of the American Journal of Medical Genetics, 2014
- Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 UpdateClinical Pharmacology & Therapeutics, 2014
- Clinical Implementation of Germ Line Cancer Pharmacogenetic Variants During the Next-Generation Sequencing EraClinical Pharmacology & Therapeutics, 2013
- Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 UpdateClinical Pharmacology & Therapeutics, 2013
- CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research NetworkClinical Pharmacology & Therapeutics, 2011
- The Path to Personalized MedicineThe New England Journal of Medicine, 2010
- The interface between pharmacoepidemiology and pharmacogeneticsEuropean Journal of Pharmacology, 2000